2009
Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC)
Socinski M, Stinchcombe T, Halle J, Moore D, Petty W, Blackstock A, Gettinger S, Decker R, Khandani A, Morris D. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2009, 27: 7528-7528. DOI: 10.1200/jco.2009.27.15_suppl.7528.Peer-Reviewed Original ResearchNon-small cell lung cancerEpidermal growth factor receptorC therapyCohort IICohort IStage III non-small cell lung cancerVascular endothelial growth factor (VEGF) pathwayEndothelial growth factor pathwayPhase II regimenOverall survival rateCell lung cancerOverall response rateIncorporation of bevacizumabGrowth factor pathwaysConcurrent carboplatinGrowth factor receptorPrimary endpointPrincipal toxicityThoracic radiotherapyPS 0Lung cancerPrimary toxicityTreatment paradigmTumor volumeConformal radiotherapy
1973
Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu)
Young R, Walker M, Canellos G, Schein P, Chabner B, Devita V. Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu). Cancer 1973, 31: 1164-1169. PMID: 4705154, DOI: 10.1002/1097-0142(197305)31:5<1164::aid-cncr2820310519>3.0.co;2-4.Peer-Reviewed Original ResearchConceptsPrior therapyMultiple dosesClinical trialsCumulative marrow toxicityObjective therapeutic responseHepatic side effectsSingle oral doseReticulum cell sarcomaInitial clinical trialsPrimary brain tumorsPreliminary clinical trialsMarrow suppressionHodgkin's diseaseOral doseCell sarcomaMarrow toxicityPrimary toxicityTherapeutic responseBrain tumorsSide effectsPatientsConsiderable toxicitySubsequent courseMeCCNUDoses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply